A new medication found to reduce the chance of the most common types of breast cancer recurring will be available to many ...

Dr. Sara M. Tolaney breaks down key takeaways from the DESTINY-Breast09 trial that patients with HER2+ advanced or metastatic ...

At the recent American Society of Clinical Oncology (ASCO) annual meeting, interim results from the DESTINY-Breast09 trial ...

Inavolisib (Itovebi) is a new targeted therapy for HR+ HER2-negative metastatic breast cancer with a PIK3CA mutation.

Diagnosis and treatment of breast cancer can differ for patients in rural communities compared with those in urban ...

In a large Chinese trial presented at the American Society of Clinical Oncology annual meeting, neoadjuvant therapy with a ...

The official results of the BRACELET-01 (PrECOG 0113) trial have been published in Clinical Cancer Research, detailing the ...

A potentially life-saving treatment for early-stage breast cancer will become much more affordable for hundreds of ...

DelveInsight's HER2-low Cancers Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, emerging HER2-low ...

Patients with certain subtypes of breast cancer may be at higher risk for death by waiting more than 42 days after their ...

Datroway (datopotamab deruxtecan) is the first TROP2-directed therapy approved for advanced lung cancer in the U.S.

Ananda Lewis chose alternative breast cancer treatments for years before her death this month. Here’s what she tried and what ...